<SEC-DOCUMENT>0001019687-11-003145.txt : 20111004
<SEC-HEADER>0001019687-11-003145.hdr.sgml : 20111004
<ACCEPTANCE-DATETIME>20111004171737
ACCESSION NUMBER:		0001019687-11-003145
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20110930
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20111004
DATE AS OF CHANGE:		20111004

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AETHLON MEDICAL INC
		CENTRAL INDEX KEY:			0000882291
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				133632859
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-21846
		FILM NUMBER:		111124740

	BUSINESS ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE, SUITE 660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122
		BUSINESS PHONE:		858-459-7800

	MAIL ADDRESS:	
		STREET 1:		8910 UNIVERSITY CENTER LANE, SUITE 660
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92122

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BISHOP EQUITIES INC
		DATE OF NAME CHANGE:	19930602
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>aethlon_8k.htm
<DESCRIPTION>AETHLON FORM 8-K
<TEXT>
<html>
<head>
    <title>aethlon_8k.htm</title>
    <!--Licensed to: publicease-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">UNITED STATES</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SECURITIES AND EXCHANGE COMMISSION</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Washington, D.C. 20549</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">FORM 8-K</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">CURRENT REPORT</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Date of Report (Date of earliest event reported): September 30, 2011</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">AETHLON MEDICAL, INC.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Exact name of registrant as specified in its charter)</font></div>

<div align="center">
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="23%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Nevada</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(State or other jurisdiction</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">of incorporation)</font></div>
</td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="23%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">000-21846</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Commission File Number)</font></div>
</td>
<td align="left" valign="bottom" width="4%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="23%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">13-3632859</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(IRS Employer</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Identification Number)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="29%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="23%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="29%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">8910 University Center Lane, Suite 660</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">San Diego, California</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Address of principal executive offices)</font></div>
</td>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="23%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">92122</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(Zip Code)</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Registrant&#8217;s telephone number, including area code: (858) 459-7800</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Not applicable</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">(Former name or former address, if changed since last report.)</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="76%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="76%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="76%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="76%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;<font style="DISPLAY: inline; FONT-FAMILY: wingdings">o</font></font></div>
</td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="76%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">FORWARD-LOOKING STATEMENTS</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>This Form 8-K and other reports filed by Registrant from time to time with the Securities and Exchange Commission (collectively the "Filings") contain or may contain forward-looking statements and information that are based upon beliefs of, and information currently available to, Registrant's management as well as estimates and assumptions made by Registrant's management. When used in the Filings, the words &#8220;anticipate,&#8221; "believe," "estimate," "expect," "future," "intend," "plan" or the negative of these terms and similar expressions as they relate to Registrant or Registrant's management identify forward-looking statements. Such statements reflect the current view of Registrant with respect to future events and are subject to risks, uncertainties, assumptions and other factors relating to Registrant's industry, Registrant's operations and results of operations and any businesses that may be acquired by Registrant. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 45.8pt"></font>Although Registrant believes that the expectations reflected in the forward-looking statements are reasonable, Registrant cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, Registrant does not intend to update any of the forward-looking statements to conform these statements to actual results.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="9%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ITEM 1.01</font></div>
</td>
<td valign="top" width="69%" style="TEXT-ALIGN: left; TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ENTRY INTO MATERIAL DEFINITIVE AGREEMENT</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>On September 30, 2011, Aethlon Medical, Inc. (the "Company") entered into a contract with the United States of America, issued by SPAWAR Systems Center Pacific, pursuant to a contract award from the Defense Advanced Research Projects Agency (&#8220;DARPA&#8221;). Under the DARPA award, the Company has been engaged to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that often results in the death of combat-injured soldiers. The contract program will utilize the Aethlon ADAPT<font style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top">tm</font> system as a core technology component underlying an extracorporeal blood purification device that selectively clears multiple sepsis-enabling particles from circulation to promote recovery and prevent sepsis. Under the contract program, the Company will also introduce a novel blood pump strategy to reduce or eliminate the systemic administration of anticoagulants normally required during extracorporeal device therapies.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>The award from DARPA is a fixed-price contract with potential total payments to the Company of $6,794,389 over the course of five years, including payments of up to $1,975,047 in the first year. Fixed price contracts require the achievement of multiple, incremental milestones to receive the full award during each year of the contract.&#160;&#160;Under the terms of the contract, the Company will perform certain incremental work towards the achievement of specific milestones against which the Company will invoice the government for fixed payment amounts.&#160;&#160;Assuming all such work is performed according to the contract terms, the Company will receive up to $1,975,047 of contract payments during the first twelve months of the contract with the aggregate payment amounts in years two through five varying between approximately $775,000 and $1.6 million. The milestones are comprised of planning, engineering and clinical targets, the achievement of which in some cases will require the participation and contribution of third party participants under the contract.&#160;&#160;The Company will be subject to quarterly reviews by the government to assess performance, milestone achievement and any required modification of the milestone and payment schedules under the contract. There can be no assurance that the Company alone, or with third party participants, will meet such milestones to the satisfaction of the government and in compliance with the terms of the contract or that the Company will be paid the full amount of the contract revenues during any year of the contract term.&#160;&#160;The Company intends to commence work under the contract immediately and anticipates receiving initial revenues under the contract in the&#160;quarter ending December 31, 2011.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font id="TAB1" style="MARGIN-LEFT: 36pt"></font>On October 3, 2011, the Company issued a press release announcing the award of the DARPA contract. The full text of the press release is set forth in Exhibit 99 attached hereto.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="top" width="9%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">ITEM 9.01</font></div>
</td>
<td align="left" colspan="2" valign="top" width="69%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">FINANCIAL STATEMENTS AND EXHIBITS.</font></div>
</td>
</tr><tr>
<td align="left" colspan="3" valign="top" width="78%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">(d) EXHIBITS</font></div>
</td>
</tr><tr>
<td colspan="2" valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="10%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">EXHIBIT NO.</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" colspan="2" valign="top" width="10%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Press Release dated October 3, 2011</font></div>
</td>
</tr><tr>
<td colspan="2" valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td colspan="2" valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">SIGNATURES</font></font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td align="left" valign="bottom" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="36%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160;AETHLON MEDICAL, INC.</font></div>
</td>
</tr><tr>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">By:&#160;<font style="DISPLAY: inline; TEXT-DECORATION: underline">/s/ James A. Joyce<font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font><font id="TAB2" style="LETTER-SPACING: 9pt">&#160;&#160;&#160;</font></font></font></div>
</td>
</tr><tr>
<td valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="36%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">James A. Joyce</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="2%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="bottom" width="1%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Dated: October 4, 2011</font></div>
</td>
<td align="left" valign="bottom" width="3%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td align="left" valign="top" width="36%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Chief Executive Officer</font></div>
</td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#160;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">EXHIBIT INDEX</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div>
<table cellpadding="0" cellspacing="0" width="100%" style="FONT-FAMILY: times new roman; FONT-SIZE: 10pt; FONT-SIZE: 10pt; FONT-FAMILY: times new roman">
<tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td align="left" valign="top" width="10%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">EXHIBIT NO.</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">DESCRIPTION</font></div>
</td>
</tr><tr>
<td align="left" valign="top" width="10%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">99</font></div>
</td>
<td align="left" valign="top" width="67%">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">Press Release dated October 3, 2011</font></div>
</td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr><tr>
<td valign="top" width="10%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
<td valign="top" width="67%"><font style="DISPLAY: inline; FONT-FAMILY: times new roman; FONT-SIZE: 10pt">&#160; </font></td>
</tr></table>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>aethlon_ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<html>
<head>
    <title>aethlon_ex9901.htm</title>
    <!--Licensed to: publicease-->
    <!--Document Created using EDGARizerAgent 5.4.1.0-->
    <!--Copyright 1995 - 2009 Thomson Reuters. All rights reserved.-->
</head>
<body bgcolor="#ffffff" style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">
<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><img src="aethlon_ex99010.jpg" alt=""></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"><font style="DISPLAY: inline; FONT-WEIGHT: bold">For Immediate Release</font>:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">Aethlon Medical Receives Government Contract Award from DARPA</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 12pt; FONT-WEIGHT: bold">&#160;</font><br>
&#160;</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Contract Program Will Support The Development of an</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Aethlon ADAPT&#8482; Sepsis Prevention Device</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">San Diego, October 3, 2011 &#8211; Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that it has been awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers.&#160;&#160;The contract program will utilize the Aethlon ADAPT&#8482; system as a core technology component underlying an extracorporeal blood purification device that selectively clears multiple sepsis-enabling particles from circulation to promote recovery and prevent sepsis.&#160;&#160;The resulting device, which is being advanced under DARPA&#8217;s Dialysis Like Therapeutics (DLT) program, is expected to dramatically decrease the morbidity and mortality of sepsis, thereby saving thousands of lives and billions of dollars in the United States each year. Under the DLT program, Aethlon will also introduce a novel blood pump strategy to reduce or eliminate the systemic administration of anticoagulants normally required during extracorporeal device therapies. Worldwide, more than 18 million cases of sepsis are reported every year, with more than six million resulting in death.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">&#8220;We are truly honored to receive this contract award and look forward to working with DARPA and other DLT team participants to advance this important therapeutic endeavor,&#8221; stated Aethlon Medical Chairman and CEO, Jim Joyce. &#8220;The award also reinforces the expansive capabilities of our ADAPT&#8482; system, increases the breadth of our product pipeline, and transitions us from a development-stage to revenue-stage organization.&#8221;</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Aethlon ADAPT&#8482; system, introduced earlier this year, is an adaptive dialysis-like affinity platform technology that provides the foundation for a new class of therapeutics that selectively target the clearance of harmful agents from the entire circulatory system without the loss of essential blood components.&#160;&#160;Therapies that evolve from the Aethlon ADAPT&#8482; system overcome the historic limitation of extracorporeal strategies that indiscriminately adsorb or remove particles solely by molecule size.&#160;&#160;In function, the device platform allows the immobilization of single or multiple affinity drug agents in the outer-capillary space of plasma membrane technology as a means to provide rapid real-time clearance of corresponding targets without adding drug toxicity or interaction risks to established therapies.&#160;&#160;Beyond providing a novel regulatory and commercialization pathway for affinity drug agents, Aethlon ADAPT&#8482; therapies can be implemented for use within the global infrastructure of dialysis machines and CRRT systems already located in hospitals and clinics. As Aethlon advances its current pipeline of therapies toward market, the company will seek to further leverage its ADAPT&#8482; system to generate revenue through future government contracts or grants, and collaborations with organizations representing the pharmaceutical, biotechnology and medical device industry.&#160;&#160;The Aethlon award from DARPA is a fixed price five-year contract valued at $6,794,389 with year one revenues of approximately $2 million.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Aethlon Medical</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT&#8482; System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT&#8482; product pipeline includes the Aethlon Hemopurifier&#174; to address infectious disease and cancer; HER2osome&#8482; to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="FONT-STYLE: italic; DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Certain of the statements herein may be forward-looking and involve risks and uncertainties. Such forward-looking statements involve assumptions, known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Aethlon Medical, Inc. to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements.&#160;&#160;Such potential risks and uncertainties include, without limitation, the ability to achieve the goals set out in the DARPA contract, the ability to demonstrate ex vivo effectiveness of the Aethlon Hemopurifier&#174; to remove immunosuppressive exosomes from the blood of advanced-stage cancer patients, future therapeutic trials in cancer patients, future human studies of the Aethlon Hemopurifier&#174; as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier&#8217;s&#174; ability to capture exosomes and the impact it may have on disease conditions, the Company&#8217;s ability to raise capital when needed, the Company&#8217;s ability to complete the development of its planned products, the ability of the Company to obtain FDA and other regulatory approvals permitting the sale of its products, the Company&#8217;s ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company&#8217;s proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company&#8217;s Securities and Exchange Commission filings.</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt"># # #</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="center">&#160;</div>

<div id="PGBRK" style="TEXT-INDENT: 0pt; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt">
<div id="FTR">
<div id="GLFTR" style="WIDTH: 100%" align="left"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>

<div id="PN" style="PAGE-BREAK-AFTER: always; WIDTH: 100%">
<div style="TEXT-ALIGN: center; WIDTH: 100%"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>

<div style="TEXT-ALIGN: center; WIDTH: 100%">
<hr style="COLOR: black" noshade size="1">
</div>
</div>

<div id="HDR">
<div id="GLHDR" style="WIDTH: 100%" align="right"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 8pt">&#160; </font></div>
</div>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Contacts:</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">James A. Joyce</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chairman and CEO</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">858.459.7800 x301</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">jj@aethlonmedical.com</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Jody Cain</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Senior Vice President, Lippert/Heilshorn &amp; Associates</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">310.691.7100</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">jcain@lhai.com</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Jim Frakes</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Chief Financial Officer</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">858.459.7800 x300</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">jfrakes@aethlonmedical.com</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block"><br>
</div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">John P. Salvador</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">Director, Communications &amp; Investor Relations</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">858.459.7800 x307</font></div>

<div style="LINE-HEIGHT: 1.25; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 10pt">jps@aethlonmedical.com</font></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>aethlon_ex99010.jpg
<TEXT>
begin 644 aethlon_ex99010.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_X0!F17AI9@``24DJ``@````$`!H!!0`!
M````/@```!L!!0`!````1@```"@!`P`!`````@```#$!`@`0````3@``````
M``!@`````0```&`````!````4&%I;G0N3D54('8U+C`P`/_;`$,``@$!`0$!
M`@$!`0("`@("!`,"`@("!00$`P0&!08&!@4&!@8'"0@&!PD'!@8("P@)"@H*
M"@H&"`L,"PH,"0H*"O_;`$,!`@("`@("!0,#!0H'!@<*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"O_``!$(`'H!
M20,!(@`"$0$#$0'_Q``?```!!0$!`0$!`0```````````0(#!`4&!P@)"@O_
MQ`"U$``"`0,#`@0#!04$!````7T!`@,`!!$%$B$Q008346$'(G$4,H&1H0@C
M0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-45597
M6%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJ
MLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X
M^?K_Q``?`0`#`0$!`0$!`0$!`````````0(#!`4&!P@)"@O_Q`"U$0`"`0($
M!`,$!P4$!``!`G<``0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B
M<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G
M:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>X
MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@`,`P$`
M`A$#$0`_`/W\HHHH`****`"BBB@`HHHH`****`"BBB@`HHHH`****`"BBB@`
MHHHH`****`"BBB@`HHHH`****`"BF>8WH*POB'\3/!GPI\+WGC?XA^)[#1](
ML(?,NK[4)Q''&/<G\L#GZTXQE.2C%-M].I,IQ@KR=EW-Z0A4+,<#U-5VO;.-
MLO,![]A7YD_M;?\`!PUX;T:YNO!W[)7@6#7&5BG_``E.OK)';9YYA@!#R<X(
M+%1_LD5^?WQM_;__`&POV@KJ5_B-\>=?>UE_YA>FWK6=HH[#RH2JMCL6R>>M
M?IN0^$G$^>0C6K)4:;VYM_6VY\5F?'64X*;ITKU)+MM]Y_0/XN_:#^`W@8R-
MXT^-7A/2!'DR'4_$%M!LQUSO<8KEA^W?^Q+N"C]K_P"&;$G`"^-K`G_T;7\X
M-U=75[*9[RYDED8Y9Y7+%CZG.:C"@'/\@!7W]#P&PG)^]QLN;RBO\SYF?B3B
MG+W<.O\`P)G].7A?XX_!CQP$;P5\6_#6KB3&S^S-;@GW?38QKJEN('3(/!]J
M_EJL]1O].NEO=/OIH)D/R2PRE67\1S7N'P+_`."E?[:?[/MU!_PA_P`=M9O;
M"!AC2/$%VU]:[?[NV8DJ/]T@UXN9^!.8X>#J8+%*;724;/[U<[<)XC4G*U>C
M9=TV_P`S^BN`H5S&1C/:GU^;O[(/_!P+\+O'=Q:^#?VH?#*>$M3N'$::[8;Y
M=.D<CC<IS)#D_P"\HSR0.GZ%>%O&>A^,M$L_$?AG6+34+&^A66VO+&<2Q2H0
M""K`X(P17Y)G.09OD%;V>.I.#>SMH_1['WF5YQ@,WH\^&G?RZKU1L44P2DGC
M%.4Y&:\9.[L>K9H6BBBF(****`"BBB@`HHHH`****`"BBB@`HHHH`****`"B
MBB@`HHHH`****`"BBB@`HHHH`****`$9U3[S8S2>;&1G=UHD`(&17$?'CXV^
M"/V>/AEK7Q;^(VH"TT;1+$SW,PY8GHL:CNS,0H'J154J=2O6C2I*\F[)+=M[
M6,ZU6%"FZDW9)79R/[9O[9WPC_8T^$]Q\1/B/K8^TNC+I&C6SJ;K49@,A(E)
MZ<C+'Y5R,]1G\+/VS_V\_CQ^VWXQ?6?B?K;0Z-;SEM&\,V4I%I9IGY>/^6DF
M.LC<YSC`K,_;(_:[^(W[9OQEOOBOX_NI(X6;RM%TA)BT.G6P^[$G;<>69CR6
M)Z#BO**_K+P[\.,#P]@HXK'4U+$RUUU4?3^F?A?$_%.(S?$.E1=J*[:7]0R2
M,DYHHHK]<U/CDK*P4444#"@$CH:**)1TT8`?F^]SQCGTKZ,_82_X*2_&[]B'
MQ+%9:)J5QK/@VXF)U3PK<393!(+2P$_ZJ7KS]TYY'>OG.@$J<J<'L1V->/G&
M58'.\'+"XV"G!]U^/KV>YU8+&8C`8A5J,K21_2O^S%^TM\)OVH_A;9_%7X4^
M)DO+&Y7;<02-B>SE'WH94R2CC/3N,$<$&O2H)8YHA)$P(/<5_.]_P3P_;J\:
M?L0?&:#Q':33W7A35)8XO%6AQ.0)X1P)47H)8P25/I\IXK^@;X<>//"_Q'\"
MZ1X\\%ZE%?:3K%A'=6%Y;ME)8W4,I'?H>G4<@\BOX_XYX)Q/!V:.&]&>L'OZ
MQ;[K\3]WX8XBI9]@[O2I'=?J;U%%%?#GTX4444`%%%%`7044TR8!^7I[TTW"
MC`(`_P"!"E=7L!)14?VE0Q4K^1IWF?[/ZTQ70ZBO/OVG?VI_@1^QO\&=7_:$
M_:2\>1>&?!V@^1_:NLS6<]P(#-,D$0\N!'D<M)(BX52?F]*X[]A7_@HE^S%_
MP4=\!:[\4_V4O$VH:UX<T'Q(^BRZK>Z1-9+<SK!%,6CCG59-FV91EU4Y!XHW
M&>XLZ)R[@?4TBR1MPLBGZ&N)_:4\0Z[X0_9^\;^+O#&H-::CI7@_5+NQNHP"
MT,T=I(Z.`002&4'GCBOPX_X->/\`@J__`,%"/VYO^"A>O_"#]J?]IO6?&'AV
MR^%.H:O;:7J%C:1HEW%?Z="DN884;(2>08SC#4`?O_1110*Z"D9T4@,X!/0$
MTM?DU_P==?MX?M;_`+"'P.^$WBW]DOXV:EX*O]=\67UIJ]QIMO!(US"EJ'5&
M$T;C`8D]*!GZR"1&)"N"0<$`]#2U\>?\$'_CY\8_VH_^"7?PQ^.OQ\\>7/B3
MQ5KEK>MJFL7<$4<EP4O9HTRL2*HPBJ.`.E?8=`7N%%%%`KH****!A1110`44
M44`17;,L?RM@G/(^E?CM_P`%^?VQ+GQU\4;+]E#P;JQ;2O#(2Z\2^3)Q/J##
M]W$>>D2$,<_Q/_LU^M'QE\?:;\*OA9X@^)>LLJVF@:/<ZA<EC@!(8F<_H*_F
M=^)WC_7/BK\2-?\`B7XEO&GU#7]9N;^[E<_>DEE9S^'S8'H`*_9?!CAVEF6>
MSS&LKQH*Z_QO9_):GYWXAYM+"Y?#"0=G4?X&&>3N/7UIT4<DTBPV\3222-M1
M$7))R``!WR3BFCFOMO\`X(C?L5G]HGX^/\:/&>BB?POX$E29([A,QWFI$$PQ
M^X3_`%C?1`?O8K^C>),\PO#N3U,=6>D%HN[Z)>K/R?+<OJYGC88:EN[7].IT
M'P._X-^OVBOBE\/K#QQXX^)VD^$+G484FBT6ZTV6>>"-@"/-Y0(_/*<X]<Y%
M=I_Q#;_%/_HZ#0?_``G)?_CM?K9;P;57#`C`QBIO)'M7\JU/%SCBI5E.%=)-
M[<L=/+5/8_:Z?`N00IJ,HMM;NY^13?\`!MI\5B21^U#H7_A.R_\`QVFR?\&W
M7Q1A7=)^U#H('JWA^7C_`,B\U^NYCP,G'`KP3_@H_P#MK>`_V!_V.?&/[4'C
MJ50-!T]QI%@9`K:AJ+@I:VJ]\O(5!(^Z`Q/W34_\18XZ?_,2O_`(_P"13X'X
M=M_#?WGXF_ML?\$^_CC^POXCM+/XCBTU31]3R-+\1:2KFVF;/^K;>H,<F.=A
M^H)KPNO>/^"77_!8+XJ?\%:?$'BW_@G1_P`%#O%NEWNH_$7S[[X4>*_[.AMO
M[*U:+=/'8$1(HV%`RQNWSG8R%G:09\;\;^#/$OPZ\8:IX#\8Z6]EJNC7\EGJ
M%K)UCE1BK#W&0>:_>?#+CBIQ7@IT,6U]8IO5[<T7L[;='<_,>*^'ED.+3I_P
MY[>3[&71117ZA%IZH^4#\.HQ7ZH_\&^W[8UQ?Q:K^QYXWU;<UHKZMX2>:4`^
M7E1/:KGDX/[T`=F<]`:_*ZO0/V4OC7JO[.O[17A'XQZ;,RC1=:AENECX+VQ<
M+,GONC+C\J^,X]X<I<1<-5</;WXJ\/)K_/8]KA_-:F49I3K1>C=GZ,_I@B?<
MQ!?)QG'I4E9^@:K:ZU90ZG8R+)#<6Z2P2J<AT900?IS6A7\1)2CI+=']&1<9
M136PV5BJY![U^9G_``52_P"#AZ\_8!_:@;]B_P"#7['GB3XH^/6T:UOT%A<E
M8`UP"8HEB@CDFF;`YP%QGC-?IG,K,F$`S[UR]A\-/AWX<\;WOQ"T_P`#:3!X
M@U:-8[_6K;3XENKB-%55624*'8*H``)_A%,;U/Q^B_X+6?\`!QSX\TP^+?A[
M_P`$3Y-.TQ25,&M:-J:W)(YR(YG@DQ@'^`Y]ZP/AO_P=U?%KX0_&&'X1?\%)
MO^"?NN_#J3S$6^N--6XAO;)&W?OWL;V-'DC^Z?D<':&(W'`/[7>-OB#X(^'/
MA>?Q7\0O%6F:'IEL%^T7^KWT=M;Q9]9)2JC\^U?S:?\`!V%_P4:_8J_;0\<_
M#?X8?LP:WI7B_6?`KZDWB3QQI*L8%CG6W$=A#,`%N5#(SLPRB$!5)+/03:Q_
M2%\-?B5X+^+GPST/XJ^`?$<&K:%XBTB#4=)U.V(*7-O-&'CD'IE2#CMTKXX_
M;&_X+5?"'X!^/I/@U\&?`UU\0O%L$_D3V^G3A;6"?'^JWH':63)`*(IQW.>*
M^?/V,/VD_$G[.7_!LQ\./'^@ZF4UN\\+2:-HEP9,&&2>^N(]ZY[I'O<>FSVI
MG_!#/PG^S!X)T#6_VC_C5\2O"UKXKNM3:ST2/Q!JT*364"J"\JK(V[=(SGYL
M`D+UY)K[WAC(<%+(Z^=8^G*K3C)0A3BVN>3WNUJDO+<^2SC-\6LSAEN&J>S;
M5Y2TT7E?0]/'_!2S_@J]:Z)_PF]__P`$VIY-',?F&&*"[%P$ZYV8,F<?],_P
MKU_]B#_@K]\$?VP?$:_##5]&N_!GC/+*FCZK(C1WC#.5MY<C<XP2495;C@-U
MKW.#]KS]E:%/+;]HGP4,'HOB&WQ_Z%7Y!_\`!8"_^$G@#]M/P_\`'?\`9@\=
M:1-=:C:0ZK>7'AR]CD6#4;><#S<Q$X9P%)&.=I/5C7JY3EN6\65YX.IE_P!5
MGRMPG#GM==)*3>_>Z//S''XO(80Q,<7[6-TI1=NO5-?Y'!_\'-__``67\=>(
MM/\`C%_P2F/[,MS#I%EJ>B+)\1#?2&.3RVL=2!$?E;<%RL7W^OO7RW_P16_X
M+W_$3_@EK^S5KOP/\*?L>7'Q`M]7\7SZT-8@U.:$0226T$1@VI"Z\>2K=<_/
M7ZZ?\'('BR7QW_P;X>-?&]PNV35X/"5Y(@&-K2:M8.1^9KS/_@RW_P"4;7CK
M_LL=[_Z;-.K\OG3E2FX2W6A]W3FJD%-=;,]Z_85_X*F>*?\`@JQ_P3L^.OQ<
M\5_`&X^'LWAO2]8TB/3+B\>?[2O]DF;S@7CC('[S;C'\-?B?_P`&IG[0'PG_
M`&6?V\/B1\>OCAXRMM`\,^'/@!K%QJ6I71)51_:VD;5`'+NQ(54`)8D`5_3Q
M^UO_`,FM?$G_`+$'6?\`TBFK^/3_`((U?L0S?\%$OV^?!G[*]YJ=W9Z!J[2W
MGC">SD96_LJU'VB9,CH7,:(I.0'=#U`-2:GZV_&G_@\,^+GCKQM=>&/V`?V#
M;[Q5ID,CQ6FK^(DN9KFZ9>L@M+)6V+@$A3*3C!.#D#A?`G_!YS^U)X$\6P:+
M^T]^PUH`MO-8W<6B7UWIUY&G0`)="09!&"3_`#K]X/V??V<?@O\`LO>`K7X6
M_`;X8:+X3\/6,"1VNF:)9+"@"C&YL<NYY)=B68DDDDYKY8_X+X?L%?!']L;_
M`()]_$GQ#X]\$Z8WB?P3X2N]=\)>*1!LO=/GM(VFV"5?F:*15=&C/RD-G&X*
MR@FKGM_[`/\`P4"_9_\`^"C_`,";/]H7]G3Q!<76CW%P]K>V-_`L-WIMT@!:
MVN(PS;)`&5N"5((*DCFORQ_X/=/^3:?@A_V/.H_^D8KQ[_@R,^)&MP_&KXY?
M",WT[Z;=>%M+U=;<R'RXYXKB2$N%_O,LR@GT0>E>P_\`![I_R;3\$/\`L>=1
M_P#2,4`S[/\`^#:+_E"_\&O^O+4?_2^>O=O^"A/_``4?_9A_X)I?!Q?C-^TQ
MXW-A:W,CPZ1H^GQ+/J.K3*`3%:P%EWD!@68E40$%F'&?!/\`@VO0R?\`!%7X
M.H,Y^PZAT/\`U$)Z_%3]L3QSXQ_X+J?\'!5A^S*?&URG@Z+QK-X4\/"*1BMA
MI%@LDE_<Q*V`LLPM9Y>QR8T)(7)"4['UGJ__``=N_MP?'WQ;>:!^P;_P3)O/
M$=O;MB,36U_K-[M#8+2P6$8$1.5XW-M)QEN#4GA+_@[X_:F^"'C^W\&?M_\`
M_!.&^\,Q;E6]&G1WFEZC$&(.];74$PV$W$*77<0/F4'-?M3^SK^S/\%/V5/A
M1I7P:_9Z^'&E^&?#FD6D<5G8:;;J@DVJ%\V5_O32,`-TCEG8Y)))S6#^V7^Q
M7\`?VX_@CJOP+_:&^'MAKFE:I;/%!<SP*;G396&%N;:3!:*9"0P92.F#P2"#
MMU*G[%W[>O[.'_!0/X,6_P`<OV7OB);ZWI#2"#4(63R[K3+HA6-M<PDEHI`&
M!P>"&!4L.:\P_P""R'_!3G4/^"4_[*-I^TM8_"M/&377BNTT;^RGU$VH431S
M/YN\(_3RNF.]?A?_`,$2?BS\4?\`@E!_P7:UK]@KQCXBGF\/^(O&M[X'\16[
M`+%=RQ22#3=152?D)<1D'_GE<N.N,?I3_P`'BC[/^"4^EL'*D_%;20&!Q@_9
M[SF@;=C0\)?\'0_[.FB_\$\-$_;>_:`\"7.B^(/$_B#4]+\+?#'P[?QW=]J;
M6DB1F7?*(Q%""X+RL,`9"AVVH?C[Q=_P=W_\%$?%+W?BSX+_`/!.;2[?PQ;2
M'_3=1M=3OQ'&3\ADFB6*-3C'(X.>*\\_X-3O^"7/PX_;%\0^(?VO_P!IOPU;
M^)_"_P`-;Y-&\$>&M;B\ZR?4I$-S/.\;':1"LL;*A4JSSEN"@S_2)8:!9:/H
MT&BZ/86\%M!"L<-M#&L<:*.BA5&%7V`H&?A[^R)_P>;^$_%WQ%M/`'[:O[,Q
M\&Z?=W<=M)XK\*ZBUU'I[$[3)<VTP5Q&"06*,S*H/RL<"OW"\)>*-"\:^%]/
M\8>&-9M]1TW5+..[T^_M)0\5S!(H>.1&'#*RD$$=00:_G_\`^#QO]@[X(?"?
MP_\`#;]L_P"'/@[3/#WB'Q#XENM!\5Q:/8I`FKEK8W$-U($`7S4$$J%L$N)5
MR?D&?T0_X-C_`(J>)/BW_P`$:?A5J7B:X>6;17U+18))'+,;>TOIHHER>>$"
MJ/0*!VH`]3_X+4?$&?P#_P`$]_&:6MUY,FMFVTI6SU$TRAU^A0,#]:_`D`#[
MO0]!^E?MU_P<'R2+^PQ;Q*P"2>,;$29&<@+*1^H%?B(IR,XQP._L*_J;P3HP
MI<-5:JW<W?[DC\1\1:DJF=0@]HI?B:/A+PCX@\?^*=.\#>%-.DO-3UB]BL["
MTB4EII9&"JH'N37]%?["W[+'AK]DO]FSP_\`"#3(DDO+:W%QK=XO6ZOI`&FD
M)[C=P/917YU?\$"?V+HO&GCB^_:Z\<:8'L-"E:S\*),G$MZ>)9USU\M<J/1F
M;TK]>K52D>TH!]*_/_&/BI9IFBRO#S_=TOBMUD]ON7XGTW`&2?5L,\?4C:4]
M(^2[_,$`!`J2BBOQA))61^D#92OEMD_PG-?S!?\`!V?_`,%-O^&E?VJ+/]B?
MX6^(Q<>#?A-<L=:EM90T.H:[(@\PY!.[[.A\GGI(TP]S^V__``6[_P""C^B_
M\$S?V(?$7QHLKR!O&&J_\2;P)ITK<W&I3(VV7&#E(4$DS$\'8%SEP*_C<\1:
M]JGBC6[OQ)KNHS7E]J%U)<WMU<.6DFF=BSNQ/5F)R3[TP+O@?XB^-OAKXPTG
MQ_X$\27.EZSH6HQ7^D:A:2;9+6XC8.DB'L0P!_"OW8_:>\4>%_\`@H!^R?X$
M_P""KOPML+:&Z\10)H7Q=T>P4!=*U^W4(TI0$E$D`!&XD[7B.?F.?P-K])_^
M#>K]M?P9\./CMKO[!W[0>L[?A;\>K/\`L.X^TRXBTK6S\ME>KGA6+$1$\#+1
M,Q_=\_2<)Y_6X:SRECH-\J=IKO!_%_P#P^(LJAG.55,.U=VNO)HZVBNO_:!^
M"WBK]G/XR>(O@SXUMRE_H.I20,Y7`GCSE)E]5=2&!]#7(?48]C7]OX/&4<9A
MX5J+O&23379ZH_G>K2G1J.G-6:T^X*,9XP/QHI&QM.1D8Y'K7;/EG!Q:T,9/
MEM+L?T9?\$W/'<WQ+_8E^&OC.ZF\R:?PI;P3/G.6@S"1^!0U[G7RE_P1-D:7
M_@FM\.F9RV#K"AB<Y`UB]%?5M?P/Q#0AAL^Q=&.T:DTO12:/Z8R:I*KE-"<M
MW"+_``,;XA^.O#GPP\"ZO\1O&.JPV.D:%IL]_JE[<-A(+>&-I)'8G``"J3SZ
M5_/-\?\`_@X6_P""IO\`P53_`&FKC]E3_@DEX,N/"FBW$MP-*OM-LHVUF[LH
M\DWMW<S$PV$14`X7;M+A3(Q8"OW7_;Y^%GB/XZ?L-_&/X(^#EC.L>,OA;X@T
M/2!*3M^UW>G3P0YQV\QUK^;/_@VD_;T^`G_!,7]M7Q[X`_;1\WP;_P`)9I0T
M(^(-2M7V:)?VUR6:"Z`&Z)'92C-@A71-VU<L/'/2/M[X6?\`!J)^T'^T1JEM
M\0/^"IW_``4?\6^+]2DPT^B^&=4GO3`K,28DO-2!"@$\;+<`$X`(YKP?_@YE
M_P""5W[%7_!,O]BGX4:5^RE\+3IE]K'CZ>+7/$&IW[WFH:@L=E(4$DK\!06)
MV(J)D_=X&/VQU+_@KU_P2YT#PM%XNU;]O?X4Q6$D6Z.>/QC:OYGREB%56+,<
M`X`&3V'(K\N/^#POXM?#OX]_L`_L\?&+X2^(TUCPWXF\77&I:'JD=O)$MW:2
MZ:7BE"2JKJ&4@@,H//2@5T2Z)HVJZO\`\&P/P"O],A)BTW7XKB[=,_NHVFU*
M+/7^_*@_&O;/^"4O_!,K]BC]KS]E"V^)?Q3\,ZM>^(;?6KVRU-[77)X$&R3=
M'A$;`_=NG/<YKN?^"/?[/^C_`+3O_!O3\-O@CKTGE0Z[X.NXH+D(";>=;Z9H
MI0.^UU4X[\U\Y?L0_M7?$S_@D9\>O$?[/G[3G@S48_#VI7B-?"$$_995^5+R
MW'26-T(R`<GC'*XK]:X9Q>-Q_!%?+LLJ..*I5%444[.4;6LNO?;R[GY]G=##
M87B6GBL5#FH3C9Z:)^?_``3[LC_X(0?\$Z74G_A7VO?AXINA_P"S4J_\$'?^
M"=D>`O@'7E'HOBNZ_P#BJ]!\-?\`!53_`()\ZYH,6MP_M2>&;>.2,-Y-]+);
MS+GL8Y%#Y_"L&#_@KE^QEXM^*OASX,_"7QY>>+M<\1:U!IUO%HVE3>3"TCA3
M*\LRHI5`2YVEN%-?,2Q'B%[TFZZY5K=3LDMVWT1ZZH<'*RBJ=WLDXW?RN>"?
M\'.OA71_`W_!!GXB^#?#\+1V.E7'A>TLXW<L5BCUFQ502>2<`<UX]_P9;_\`
M*-KQU_V6.]_]-FG5]`_\'.GAGQ!XT_X(F_&&R\,Z1/>W%HVAW\L-O&79;>'6
MK*263`_A2-6=CV523P#7Y>?\&PO_``6F_8N_8`^"GC7]FS]K_P"(4W@ZUO\`
MQ)_PD.A^(#HMW>PW#R00V\MLZVD4LBN/*1U8KL(WC((&?C7)S?,W=L^HC%12
M45H?T"_M;_\`)K/Q)'_4@ZS_`.D4U?S<_P#!F/%%+_P58\3N\:EH_@=JY1B.
M0?[5TH9'O@D?0U^YG@[_`(*._LF?\%%/V0/CAXP_9'^(5SXGT3PMX3U+3]0U
MF71;FRA>XDTV:79&+E(Y&VJ5R2@&6&">WX;?\&8R-'_P55\5EQC'P/U93[$Z
MMI/%(L_J%8D#(KQ'_@I.<_\`!/;XWD_]$IUW_P!(9J]N<$CBO#_^"E$J+_P3
MY^-\9)S_`,*IU[M_TX3?XT`]C\+/^#)90O[8OQG`_P"B:6G_`*<(Z^@_^#W3
M_DVGX(?]CSJ/_I&*^?O^#)H%?VQ?C-NXS\-+4#/MJ$>?Y5]`_P#![B#)^S9\
M$(T&3_PG&HG_`,DQ01KU/LC_`(-M(3<?\$3_`(00*Q!?3=24$'GF_N*_%3_@
M@YJ%I\-/^#CT>&_B%8/'J=WXI\7Z7;FZ&UHKTQW;ACGD,RQNON7QWK]K_P#@
MVK/E_P#!%_X-PR*=WV34!M]_[0N/\#7Y6_\`!Q1_P3T^/G_!/#_@H!I__!6G
M]EW1;V/PWKGBJWU^^U.PA\Q?#WB)&C+><H8D0W+@N&/R[GE3*Y3<"6I_2':L
M6MT9CG*CGU]Z+G[@P>IK\Q?V&_\`@Z3_`."9_P"TC\/]*;X__%9?A+XW:!8]
M5T+Q+:W!LS,%4N\-Y'&83$6SM\TQL!V[GGO^"BW_``=3?L#_`+/_`,)]8TG]
MCWXC)\5/B)-9R6^AQZ9IUPFE6-PRJ$GN+F:-5F5-V\)#OWE-A:/.X!>MC\J?
MVQ;*?XQ?\'5]]I/PQU037,G[0^A6RW-K(1LEM#9QW*97NK03(?=37ZH_\'C9
MQ_P2BTLX'_)5M*_])[ROD;_@UX_X)G_&3XW?M2:I_P`%:OVG]$O!9PWU[>>#
MY]7@9)/$&K7A8SZF`V"T:+-)M<CYI)=P)*5]<_\`!XP?-_X)2:8L?)_X6KI7
M'_;O>4$ZF[_P:&:%IUG_`,$@K#5+>$+-??$36Y+E@`-[*\2*3@9/RJ!S7ZC*
MH50HZ`8K\Q?^#1;C_@CEHH_ZG_7?_1R5^G=!9^+W_![+_P`F+_"3_LK#?^FN
M[KWK_@TZ_P"4+'@/_L:/$/\`Z<YJ\%_X/8QN_89^$B#J?BNYQ_W#+K_&O>?^
M#3QUC_X(M^`T<X;_`(2CQ!\O?_D)ST`>O_\`!=OP?<>*?^"?&OW]NA/]C:M8
M7TF%SA1,(S_Z,%?B=\"O@[XO_:!^+.@_!SP%;"74]=OTMH"5)6)3RTK8_@50
M6)]%K^C;]K/X51?'']F[QI\(Y(0[^(/#EW9VX*@XF:)O*;GN)`K#W%?!_P#P
M09_86U/X=Z5K'[4OQ-\.F#5[N6;2/#45S$`UO;1L4GF`[&1UV#_91CT:OVC@
M?C:APWP5C(?\OE+W$^O-&U_^W6KGYKQ-P]5S7B2A9>Y)>\^UNGS/OK]GOX&^
M#/V=OA)H/P:\!V_E:;H.G+;P$J`\C<EY'QQO=BS$CNQ]:[E$"#`)_&EP#SCZ
M45^-5:DZ]656H[R;;;[MGZ-2I0HTU""LDK(20E4+`@8]:JW>H-;)O,B``$L6
M'``&>:L7#*D+,PR`.17Q_P#\%BOVTK?]E3]F&YTCPIJ2P>+O&2RZ=H`1\20Q
M@#[1<@=?D1L`_P!]U],5U99EV*S;,:6#PZO*<DE^K^2.?'XVEE^$G7J/2*?W
M]#\3_P#@Z4_:%UC]L?XZ1ZKX$UB>Y\'_``R,VD0V<,I:&>X>3$]\`,@_.J1;
MNR*F/O-7X_2Q"-<[6!SCFOU'UW1=/\1Z5=Z#K<:W%O>0M#=)+_&#D$Y]\Y^M
M?G/\=OAKJWPJ^(U_X.U)'(BFWVTSKCSHFY5_R.#Z,".U?J'B5P%0X6I4,3A$
MW2:4)/\`OI;^DE?YGR7!O$TL[A4I5OC3;7I?]#C*MZ-J5SI>HQZA:SF.:)M\
M,RL0T3C[KJ1R"#@CZ55\M\$XZ'%("0<@U^17/N3]Y8OBQ9_\%3/^"9GA3]M;
M39([GXH_"2UMO"OQFAB`\V\A0*+34V4<MO7!+=,M(!@(#7S:,`87ICBO!O\`
M@A-^WWX?_8<_;$MM/^+S)<?"WXE6S>&/B587#8B%G."L5TV1@>1*5<GCY/,&
M1D$?9_[:?[,^K?LF?M#ZW\);IWN=.247?A[4<`K>:?+\T,@(X;Y25..C*?7%
M?TKX,<5K$X:63UW[\-87_EZKU3V\F?CO'N2?5L4L?27NSTEY/O\`,\JHSCG&
M<=O6BMWX7^`]9^*7Q)T'X:>'83)?Z]J]O8VJ`9^:60(#]!G)/;%?N>)Q$,-0
MG5D](IM^22OJ?G=."JU%#NTOO9^_O_!*+P=+X$_X)_\`PQ\/SP>4Y\/&[>,C
M!#7,\MP3CW,IKZ*K`^&_@_3/`'@[2?!6BQ[;32=+@L[8$<[(D"+^@K?K^!,R
MQ;Q^8UL2]YSE+[VV?TUE^'>$P%*B_LQ2^Y$5W;?:H?)\PK\P.0/0_P"?QKY,
M_;'_`."&G_!,S]NSQ7+\0_C_`/LWV$_B6Y*F\\1Z%=S:;>71484S/;.GFD<<
MN"3@#H`!]<45Q'8?FQH__!IQ_P`$8]+F\ZY^#7BN^QC"WGCV_P`#'M&Z_P"3
M7U=\>_\`@F=^Q1^U#\)/"GP+^/7P-TWQ%X5\$1QIX7TBXEECCL`D(@7;Y;J3
MB,!>2:]YHH$TF<1\"_V?_A3^S/\`"K2/@C\#O"-OX?\`"^@Q-%I.DVK.R0(S
M,[`%V+<LS'DGK6=\</V7/@1^T;HR:+\:/AIIFOPQ9,#7=N!+`3U,<@^=,_[+
M#/>O1]J\\=>M&U<8Q54*M?#5E5I2<9+9IM/\#*OA\/B:7LZL%)=GJCXUN?\`
M@A7_`,$[KFZ>Y'PWUN!'<L+>#Q1=+&OL!NX%>C_`_P#X)A?L6_L[^*++QO\`
M##X-VEOK6FOOL-6O;F:YG@8@J2K2.<'!(S[U]!&&)CDH,TI53U45ZN)X@S[&
M4_9U<5.4;6LY-Z?><-+),IH3YX48I^2L9&N^#=#\7:)>^&O%.G6^H:=J%N]M
M?:?>0+)!/"XPT;H1AE(X(/%?`?C7_@U@_P""-/C3Q+<>)O\`A0&LZ0;FX,LM
MCH7C"^M[;DYVB/S#L7V4@5^B84#H.M#9P<5Y&IZNK9X#^R)_P3%_8W_8:^"F
MO_L^?LY_#&32?"WBB::7Q!976JW%T]\TL/D.7DE<MS'\O!'%4OV4O^"3?_!/
M[]B'XE3_`!>_9;_9QTCPCXCNM(DTNXU/3Y[AF>TDDCE>+$DC``O%$W_`!7M/
MQ2\9S?#OX>:YX]CLOM7]C:1<WOV4R^6)O*C+[=V#MSMQG!QFOFC_`()S?\%-
M[?\`;U/B;3]0^&I\(:CX>6WFBL1K;7IN[>4OB8$PQ;0&7'0YW#FNVAEV.Q.`
MJXRE3O3IV4GV;V^]G#6Q^%H8J&'F_?G>R]-7^!]=5A_$7X=>$_BMX)UCX=^.
MM*CO]&U[3)M/U6QESLN+:5&22-L$'!5B."#7Q]\"/^"ND?QV_;?O/V1_#_PB
M\O3;>^U"WL_%O]OES<_9E8EA!Y`')7&/,K,T7_@JA^U-\1?C7\0OA#\`?V#V
M\:-\/O$]WI&HWT?Q&M[/?Y-S+`LACGMUV[_*+8#-CU->M/A//J<Y1J4E%QC&
M;YI1BE&3M%W;2U>AQ+B#*Y04XSNG+ET3WM?:Q[C^R%_P2[_87_8.\5ZKXV_9
M0^`.F>#M3UNQ6SU2YT^XG8W$`<.$82R,,!AGC%;G[7_[`G[)G[>FA:-X:_:P
M^#UAXPL?#]X]UI%O?S2H+:9UVLX\MU.2!CFO)OC9_P`%`/CG^SG^QY<_M,?&
MO]EN70M>@\01:>_@N7Q?%*%BD;:LXNH8Y!@]=NTGUKC]?_X*>_MF_#+P=#\6
M_C+_`,$V]8TOP4L,4^H:[I?CRTOGM[=P")O)CCW$88'YMH'<CI7-0X?S7$0Y
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MXTI7[)7UN:SSG+:<9OVEU'EO;7XOAM;>YY+\8O\`@V2_X(Z?&;Q-<>,-0_9F
ME\/7UT6:8>#_`!#=Z=`69BS$01R>6,DG@*`!P,8J[\`?^#;'_@D!^SQXHM_&
M?A[]EZ'7]1M95EMG\::O<ZM$CJQ*MY%P[1$C@8*$''(KV?\`9L^/W[:WC_XB
MMX8_:&_8^A\$:*VFR7,6O6OC&"_59PT8%LT:*&)*LQWCCY,8KS7]NO\`X*QI
M^R+\71\+_!7P=N?&\^GZ(NJ^*I;;5S;KHUNTB)&SA8I,D[P2#M^\G/(S%#),
MSQ>.^J4(J<[7TE%JRW=[V'6SC!8?"K$5&U%NVJ=[^FY]A:5X:TS0]/@TG1K>
M.UM;9`EO;V\01(D485548``&`!VQQBO/_P!JK]C7]G/]MGX:Q?"#]I[X:6?B
MSPW!J<6H1:7?/(J"YC#A),QLK9`=N,]ZXK]IW]N#2_@3^Q0_[9'@W0E\46#:
M?IEY8V7]H_9A<0WLL$:MY@C?;@3!ON'ICBO4/@3\3I_C)\(O#/Q4DT\V)\0:
M);Z@UD)?,$/FQ*^S=@;L;L9P*XZF#Q=+"K$2A[G,X7_O15VOE='12QV&K5_8
MQE[UN;Y/8S?V6OV3/@!^Q;\+$^"?[-/P[M?"WA>*_FO(=(LI)&C2:4@R,#(S
M')('>O1ZB#G&=Q^N:\@_;?\`VG[S]CW]G+7?CW;>$#KS:-)"%TI[_P"S";S)
M53_6;'QC=G[I]*RPU&KC*\*-)7E-I+U9M7KT\-2E4J.RBKOT+'[7G["W[+'[
M>'A+2?`O[5OPDL?&&D:)J1U#3+'4)952&Y,;1^8/+=23L9ASZUL?LS_LK?`O
M]C[X467P-_9U\!6GAGPIIUQ-/9:-9-(T<4DKF21@9&9LL[,3D]Z^:_VNO^"L
MFL?LQ_`?X5?&:S^"(UIOB7IK71T_^W3";`B"&4*&\A_-),P&=JXV^_'I'B7]
MO_P>O["MY^V[\.--&OV-IH*WW]C&^,+"7>J26[R;&V,C,03L/3IS7JRX>SB%
M"E6=+W:DN2+NOBO:S[:I[]CSX9WELZTJ2GK%<S]&KW^YH^B[R#[1%Y9;`SSQ
M4%GIMKI]J+*RB2-`20J(%`R<]!]:^9/CO_P4I\"_L^_LY>!_C)XJ\,WU_KOC
MZR@E\-^#-,N1)/=RR1HQC$A4?*ID4%]N264;22!4'P=_:F_X*`^-?'.@1?$C
M]@,^&_#&L7$:7NJ)X]M[BXTJ%P<2R0>6K/CC<!M(W=!MK*619I]4E7DE&%VM
M91BY<NCY4VG+56T6X+.<`Z\81NY.VR;M=75WT/JX<#%%`Y&:ANLA21(R\#H:
M\L]8BU_4++2=$NM4U*\2WM[:!I9[B1L+&BC+,2>@`!.:_GD_X*3_`+7NH?MC
M?M1:OX\L;TMX;TN0Z=X5MFR`MI&2/-QGAI'W/]-HYQFOTB_X+L?MK3_!3X&1
M_L[>"-:*^(O'$;)J/E2$-;Z2-PD/L9&Q&/\`9$GM7XNQDD;F&">U?T9X*\)Q
MC"6>8F.K]VFG^,OT^1^1^(.=>VJ++Z4M%K*W?L*H"#"]NE>%_MS_``7_`.$]
M^'R>.=$M?^)EH2EI]G6:W)RV?4J?F'MN]:]UIEQ;P7=M):7,*R1RH4='`((/
M!!!ZBOV?/\DH9_E=7!UDFIK3R?1H^$R?,:^4YA3Q--[;^:/RTGS%(8B.G7ZU
M#7I_[3OP:F^$7Q3N]%LX_P#B7WS&YTQ@G2)F/R>^W[OOBO-O(']QOR-?P_FF
M65\HQU3!U[*4&T_\_F?T?A<32QN&AB:;O&:NA;.=;=Q(4W8/0'%?N!^QI\9(
MO^"J'_!*6W\/ZQ<_:?C/^S/:)#/D!IM9\)D$1..K,\(4H1V\H'_EKA?P^$07
MC:P_"OI7_@E5^W=XB_X)W_MI^$OVAK*>:XT+>VE^-=(4Y%_HEP46ZA(.02`B
MR*#_`!Q)T'-7DN8XO)LSI8S#NTHN^]KKM\S#-<!1S3`3PTU\2T]3ZX!##*G(
M]??O7Z!?\$"OV2KOXF_'B\_:8\3:5NT/P4&@TB21?EFU.1,'''/EQ,6]BZFO
M)_C_`/L`>(O%7[8^C^`?V9+=-7\)?%*WBU_P#JMNI^SKIEPJR.SM_"L(?G/.
MTIC#-7[7_LF_LV^#/V5?@1H'P4\$VZF#2[4&[NVC"O>7+8,L[CIN=LG'88`X
M%?T!XA^(.$K<*TZ6!J7GB8J]ND-I7[-O0_)N$^%YSSF4\1%J-)Z76[6QZ/;[
M`2%-2TBQHGW$`^E+7\SQ34;,_:->H44450!1110`4444`%%%%`!2/G:<'FEI
M)#M0MC..U*2YE8#@/VF1)_PSUXX4KNW>%-0`]LV[U^0VB^./$O["'P\^$'[7
M7@.PG\CX@?!O4O#>I"%?E.I)++]FG(SR0?)/N(2.]?M5K&DZ=KFG3Z/K%BES
M:W43Q7$$JY21&&&4CN"#BN0UG]FWX$:_X*TKX<:U\(]`NM`T9]VE:1/I<;6]
MHW/,:$87[S=/4U]-D'$=#):<J5>ESTYS3DNCCRM6^]IW/G<YR>MF4U4ISY9)
M63[.ZO\`A='YM?LB?`>?]GW]NW]GKP%K$!CU6;X6:AJ>NRMGS)+RZ>XFD+''
M)4,$YYQ&!VKE/V=M.\!7G[:_[2'_``F7[;&L?"`+\3=4$#Z5K=M:?VF?[1O`
M0WG(V[;M!&/6OUFOOA-\-M1\<67Q*N_!.FOX@L+8VUEK#6BFY@B.<QK)C*KR
M>/>N/U[]BG]E'Q+K5[XB\0_L\^$;Z^U&Z>YOKRZT.%Y)IG)+.Q*Y+$DDGN37
MNPXZ5:I5=>$KSIJ#:Y7JJCGM)-6L[+MT/+_U6JTE%4I+W9N6K:TY.5;>9\9_
M\%2=8\%ZA_P2?CA\%_&I_B%:V7B2QMSXKNM0CGEO)5G<MYCQ@*67./88KNOV
ME_\`@H;^R3X3_8:NO"=M\4=&\0Z[JO@--*L?#FDW"W,\MS);+%M95X4*6W$L
M1]TXR1BOJ%OV8?@';_#\_"6W^#?AS_A&&NOM#:"VEI]E\[.?,\O&W=GOC-5/
M"G['/[+?@77(=?\`"7P`\)Z=?0$-#=6NAPK)&P.05(7@Y`.>O`]*\NEGF2?5
M:-"M3G+V-252*3BK\W+92TT^'H=U7*\U5>56E.'OP4'=MVM?;N]6?ES\?OA%
MXW^"?[`'[+7@CXA6$]IJI^([WLMI<*5EA%Q,9HXB,9#!'`(/3\*]K^-WC'2?
MV1/^"REE^T/\>+66V\&^,?"2:=I7B.2$O!ITZQ1QLK,.$`*<]P)2>F:_0'Q_
M\'OA?\5([&/XD^`M,UI=*NA<:<-3LUG^SRC&)$W`[6X'(YXJ3QU\+_`7Q)T<
M^%_'O@[3M<TY^9+/5+59DSZ[7!&?Y5NN,HU::IU*=U.-:,VI)?Q9*7N^::.>
M/#-2EK0FER\CC?;W%L_Q/,_%G[?O[)VC>#M8\1Z/\;O#>L/I&AW.IW-II&KP
MW,WDQ*2WRHQY)*J`<9+"OS__`&7/V1OVU/VTO!?C[]J_2_BEX6\/P?&<WEEJ
M.GZ_X?:]FETU'>,(COGRH\J%&WJ(D;L*_130/V#OV./"]M>V?A_]FGP=:1:E
M;B"^2'1(@)X@ZOY;?+RNY%;;TRH->D>%O!OAKP5H5IX5\(:!;Z;IMC`(;.QL
MXA'%#&.BHJ\*!Z"O/P6>87(Z519;3?/-QUFHNT5K:UNZ3^1U8G*,3F=:,L;+
MW(IV46]WUOOL?CP?C#KH_P""1_QE_8^^),AC\4?"CQ;8V`@<_,UD=8@"]3T6
M1)$XXPR8ZU]\?L0_MB?LM6_[.7PW^'L_Q^\)QZY'X9TZR;2WUR`3_:##&HBV
M;LEMW&/6O8M>_99_9WU^^UC4]:^"_AV\NO$.P:W-<:7&SWVQU=?,./GPRJPS
MW4'M6+;?L._LF:%<P:SH7[./A&VO+.=)[.ZAT.$20R*VY75MN0P(R#Z@5V9I
MQ#E&:X2=.=.<'*HZGNVM>48J6F]KIM6VN<^`RC-<OQ$*E.4)*,>6SWT;:_!I
M?([?PC\6?AUXZUW5?"O@_P`::5J>HZ)*(]6L['4(I9+-\D;950DQG*L,,`<J
M:^</^"UTN[_@G?XS*8($UAW];J.O5/V1OV1?`?[+6D^(AX>U"]U75O%7B*?5
M]>UW4U47-W-*20K;``%4$A0!W)/)S7I'COX<>!?B9X<G\(^/O"=CK&EW.WS]
M/U&W$L,F&##*-P<$`BO!PF*PN69M2Q-*\H4Y1:NK-V:>WG8]FOAL3C<NG2K)
M*<DUILC\U_VD=,LM5\*?L%:5J5O'+;7.JV<=S%(NY74Q6"E2",$$9'XUYC^V
M_P"&O&'_``37M?BC^SCI^EW%Y\)/C%IDU]X0:%<KH^J"6,O![#:F".ZE&ZAJ
M_6"[^!'PBU2/P['JGPYTB=?"$BOX7$MBK?V6P"@&'(_=G"+T_NBI?B/\&/A7
M\7M$B\._%/P!I?B&QM[E9X+75[%+B-)0I4.`X/."1GKR:^HPG&M.E4I1J46Z
M2<W*-]VZDJD&GT<;K?I='@UN&*M6G4M42J-12?DH1@T_)V?YGYF_M66FI?">
M/]D+]KCQ1H-QJ7@CP=HFFP>(/*@:5+)L12>>0.^T9!/!,0'.0*^^O!'[;_[)
M/CF;3+/P?\??"]_=ZU+'#IMA#J\;7$LCD!4\G.\-D]"!7I#^`?!@\)IX%_X1
M6Q?1DM!:KI+VRM;B`+M$?ED;=N!C&,5P?A/]B?\`9,^'WBZ'XA>"/V<?".F:
MY;S>9;ZI9:+%'-$_]Y6`^4_2O(Q^>9?FF&A2Q,)J5/FY7%JUI2<K2OM9O='=
MA<LS#+J\IX>47"5N9-.^B2TMH_1G0^"OVC_@Y\1/B7KOP>\'>-+:^\2>&%5M
M>TJ(-YED&^Z7R,<Y]:U?B=\1/#'PN\%ZG\0?&>H)::5H^GRW=]<2'A(T4LQ]
MS@<#N<#O4/A[X5?#3PEXPU3X@^'O`FFV.N:RJC5]4M;15GO`O02.!E\>]<S^
MU;^S;X6_:T^">K_!+QGK&HV%AK")ONM,N#'(C(ZNN1T==RC*-P<5X=*.$J8J
M'.Y*D[*7?S9Z\Y8Z.$DXI.>MK;>1_/O^U[^TGXF_:T_:#\0_'#Q))(BZG<E-
M+LV8D6EFGRPQ`=L(!G'5BQ_B->9U]>_M:_\`!&']K?\`9NO+G6_!GAN3QYX;
MC9FCU'0;<FXBCY(\ZW!+@X')3<H]><5\C7EE?:==RV&I6$]M/"VV6&XB9'0C
MJ"K`$5_;W#6:Y!BLLI4LJJJ4(I)):6LMFNY_.V983,*&+F\7!J;;;O\`YD=%
M`YZ4=!DU]39M'FW2ZG&_&'X&>"?C;I]I8>+UN(S93&2WN+-U61<C!7+*PP>O
M3J!7FW_#NWX*?]#-XG_\#;?_`.,5[W5S0O#^O>*=3BT7PSHMYJ-Y,P6&TL+=
MI99">@"J"3^`KY7-N%.%<PK/%8[#P<NLI:;=]3VL'Q!GF"H*AA:TDELD?//_
M``[M^"??Q-XH_P#`VW_^,5UWP,_X(^:/^T1\1;+X9?!V'Q;J^LW<@V0K=P".
M%,@&65O(_=QC(RQ_#M7Z3_LE?\$.?VG_`(Z7MKXC^,=I)X`\.L5:07UOOU"=
M.I"09^3/K(5(SG:V,5^M7[*O[&7P)_8_\%KX.^#G@V*S\U5.HZG-F2[O7'\<
MDC<GGHHPH[`5^)\8YKX:9/1EA\MPD*M=WU5^2/XZM=MC[_(,-QKF,U4Q>(E"
MG\M5]QQ__!-#]AV7]A+]D;P;^SGK7Q%O/%]YX5LYH;75M7CC:6RBFD\TVD+J
MBL($;"J#SM50>%15^C+=#'`J$YP.M,CBCC.47&:E3[HK\'G.=6I*<M+].B^7
M0_3814(I)W%HHHI%A1110`4444`%%%%`!1110`4444`%%%%`!1110`4444`%
M%%%`!1110`4444`%%%%`!1110`4444`%%%%`#)U#1,#CIWKRWXP?L=?LS_'V
M(CXN_!3PYK<Q!'VVXTQ!<+G&<3*!(.@X#<X%>J2?</TIL8&T\=J=+%8C!UU4
MHR<9=TVG^#,:V'H8F/+5BI+LT?$_C'_@@A^P-XIEEGTK1?$V@-)G`T;72%0G
MNJS)(HQZ8KDA_P`&Y7[&V]2/BU\3N#G#:OI_/_DE7Z"4P@#.!WKWX\><6T(\
ML,;4_P#`FSR9\-9#-ZX>/W'QIX*_X(1_L#>#KB*ZU#PMKNNR1$'.LZ\Y5OJL
M(C7]*^B_A#^R[\`/@59BR^$/P>\.>'@!S+I>EQQRO_O28WL?J:]`_A_&EC[U
MYF,XBSO-5RXK$SFNSDVON.K#9/E>$?[FC&/RU'6Z%$VG'7M4E-C``X'>G5Q:
..GI6MH%%%%`!1110!_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
